Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK1 | P06493 | 13/20 | 1.00 |
| ▸ | CLK1 | P49759 | 7/20 | 1.00 |
| ▸ | CLK2 | P49760 | 7/20 | 1.00 |
| ▸ | CLK4 | Q9HAZ1 | 6/20 | 1.00 |
| ▸ | CCNB1 | P14635 | 4/20 | 1.00 |
| ▸ | PRKCA | P17252 | 4/20 | 1.00 |
| ▸ | CCNE1 | P24864 | 3/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CDK4 | P11802 | 2/20 | 1.00 |
| ▸ | CCND3 | P30281 | 2/20 | 1.00 |
| ▸ | EGFR | P00533 | 2/20 | 1.00 |
| ▸ | NPC1 | O15118 | 1/20 | 1.00 |
| ▸ | CCNT1 | O60563 | 1/20 | 1.00 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 1.00 |
| ▸ | CCND1 | P24385 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | CDK7 | P50613 | 1/20 | 1.00 |
| ▸ | CDK9 | P50750 | 1/20 | 1.00 |
| ▸ | RAB9A | P51151 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20028175 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| SCHEMBL5839925 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| SCHEMBL29386738 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| SCHEMBL5839928 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| SCHEMBL5839718 | 1.00 | CDK1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL30139897 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL2515988 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL2515986 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL30555179 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 | |
| Hydrochloric Acid SCHEMBL2515982 | 0.99 | MEN1 (1.00) | CDK1CLK1CLK2CLK4CCNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4086257-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI International (US) | 2022-11-09 | — | — | EP | disclosed |
| US-11337981-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2022-05-24 | — | — | US | disclosed |
| US-11337981-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2022-05-24 | — | — | US | disclosed |
| US-20200390772-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL | 2020-12-17 | — | — | US | disclosed |
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | SRI INTERNATIONAL (US) | 2020-07-28 | — | — | US | disclosed |
| US-20190255059-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL | 2019-08-22 | — | — | US | disclosed |
| WO-2018064545-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | SRI INTERNATIONAL (US) | 2018-04-05 | — | — | WO | disclosed |
| US-7091346-B1 | Purine derivatives and processes for their preparation | NOVARTIS AG (CH) | 2006-08-15 | — | — | US | disclosed |
| EP-0874846-B1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 2003-04-02 | — | — | EP | disclosed |
| EP-0874846-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | Novartis AG (CH) | 1998-11-04 | — | — | EP | disclosed |
| WO-1997016452-A1 | PURINE DERIVATIVES AND PROCESSES FOR THEIR PREPARATION | NOVARTIS AG (CH) | 1997-05-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11337981-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | CLK2, CLK1, CLK3 | CDK1 6/4885CLK1 2/4885CLK2 1/4885 |
| US-20200390772-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | CLK2, CLK1, CLK3 | CDK1 6/4885CLK1 2/4885CLK2 1/4885 |
| US-10722515-B2 | Dual CLK/CDK1 inhibitors for cancer treatment | CLK2, CLK1, CLK3 | CDK1 6/4885CLK1 2/4885CLK2 1/4885 |
| US-20190255059-A1 | DUAL CLK/CDK1 INHIBITORS FOR CANCER TREATMENT | CLK2, CLK1, CLK3 | CDK1 8/4885CLK1 2/4885CLK2 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.